Ustekinumab for psoriasis and psoriatic arthritis

Journal of Rheumatology

Volumn 39, Issue SUPPL. 89, 2012, Pages 86-89

  Gottlieb, Alice Bendix ^a   Goldminz, Ari Michael ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Psoriasis; Psoriatic arthritis; Ustekinumab

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; BRIAKINUMAB; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 23; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ANTIGEN PRESENTING CELL; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; CONFUSION; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HEART DEATH; HEART INFARCTION; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MORNING STIFFNESS; NON MELANOMA SKIN CANCER; NONHUMAN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHINOPHARYNGITIS; SEIZURE; STROKE; TH1 CELL; TH17 CELL; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; EVIDENCE BASED MEDICINE; HOSPITALIZATION; IMMUNOLOGY; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; EVIDENCE-BASED MEDICINE; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84864416953     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120253     Document Type: Conference Paper

References (12)

1. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duclulan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
2. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9. (Pubitemid 41113889)
3. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7. (Pubitemid 32539117)
4. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
5. Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudhonsson JE, et al. Genome-wide association analysis indentifies three psoriasis susceptibility loci. Nat Genet 2010;42:1000-4.
6. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
7. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
8. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012;11;300-12.
9. Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 2011;147:1197-202.
10. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306:864-71.
11. Gottlieb AB, Menter A, Mendelsohn A, Shen YK, Shu L, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40.
12. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al CORRONA Investigators. Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.